18F-FDG-PET/CT预测局部晚期宫颈癌放化疗后病理反应的前瞻性研究
该前瞻性研究纳入88例局部晚期宫颈癌患者,在基线、早期和最终三个时间点行18F-FDG-PET/CT,评估代谢参数预测新辅助放化疗后病理反应的价值。结果显示早期代谢参数变化可有效区分病理部分反应,早期和最终PET/CT对淋巴结残留病变具有高阴性预测值。
要点
- 早期代谢参数变化可区分原发肿瘤病理部分反应。
- 早期和最终PET/CT对淋巴结残留病变阴性预测值高。
- 基线SUVmean、早期delta TLG和最终delta SUVmax的阳性预测值分别为83.3%、67.6%和85%。
核心结论
- 在局部晚期宫颈癌放化疗后手术患者中,早期代谢参数变化可有效区分原发肿瘤病理部分反应,提示18F-FDG-PET/CT在早期个体化治疗中的潜在作用。
- 早期和最终PET/CT的高阴性预测值可能使选定患者避免淋巴结清扫术,实现「定制手术」。
研究设计与样本
- 前瞻性研究,2010年10月至2014年6月纳入88例局部晚期宫颈癌患者。
- 每例患者接受基线、早期和最终三次18F-FDG-PET/CT,行定性和定量分析,以组织病理学为参考标准。
主要发现
- 组织病理学显示40例完全反应(pR0),48例部分反应(pR1 21例,pR2 27例)。
- 基线时pR0患者SUVmax和SUVmean显著高于pR1-pR2患者。
- 早期评估时pR1-pR2患者MTV和TLG显著高于pR0患者。
- 最终评估时pR1-pR2患者SUVmax、SUVmean和TLG显著高于pR0患者。
- 部分反应组在放化疗期间和之后delta SUV参数及delta TLG显著更低,早期仅delta MTV显著更低。
关键数值与推荐
- ROC曲线分析中,基线SUVmean、早期delta TLG和最终delta SUVmax区分部分反应的阳性预测值分别为83.3%、67.6%和85%,阴性预测值分别为60.3%、90%和70.8%。
- 淋巴结评估中,早期和最终18F-FDG-PET/CT的阴性预测值分别为93.5%和92.3%。
临床怎么用
- 可利用早期代谢参数变化早期识别可能达病理部分反应的患者,辅助个体化治疗决策。
- 早期和最终PET/CT的高阴性预测值或可支持在选定患者中避免淋巴结清扫术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective study aimed to evaluate whether 18F-FDG-PET/CT performed before, during and after neoadjuvant chemo-radiotherapy (CRT) could predict histopathological response in patients with locally advanced cervical cancer (LACC) treated with CRT followed by radical surgery. METHODS: Between October 2010 and June 2014, 88 patients with LACC were enrolled. For each patient, three 18F-FDG-PET/CT scans (baseline, early and final) were acquired and evaluated by qualitative and quantitative analysis. Maximum standardized uptake value (SUVmax), SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were measured as absolute values and their percentage variation (delta) (early vs. baseline and final vs. baseline). The role of 18F-FDG-PET/CT in predicting lymph node (LN) residual disease was evaluated by qualitative analysis only. Histopathology was the reference standard. RESULTS: At histopathology, 40 patients had complete response (CR, pR0), 48 had partial response (PR: 21 microscopic [pR1] and 27 macroscopic [pR2]). At baseline, SUVmax and SUVmean were significantly higher in pR0 than in pR1-pR2 patients. At early evaluation, MTV and TLG were significantly higher in pR1-pR2 than in pR0 patients. At final evaluation, SUVmax, SUVmean and TLG were significantly higher in pR1-pR2 than in pR0 patients. Delta SUV parameters and delta TLG were significantly lower in PR group both during and after CRT. Delta MTV was significantly lower in patients with PR in the early phase only. In receiver operating characteristic (ROC) curve analysis, baseline SUVmean, early delta TLG, and final delta SUVmax better discriminated PR, providing 83.3%, 67.6% and 85% positive predictive value (PPV) and 60.3%, 90% and 70.8% negative predictive value (NPV), respectively. For LN assessment, high NPV was observed at early and final 18F-FDG-PET/CT (93.5% and 92.3%, respectively). CONCLUSION: In LACC patients treated with CRT followed by surgery, early variations in metabolic parameters effectively discriminate histopathological PR of the primary tumor, suggesting the potential role of 18F-FDG-PET/CT in early personalized treatment. The high NPV of early and final PET/CT could enable "tailored surgery" by avoiding lymphadenectomy in selected patients.
引用
- Rufini V, Collarino A, Calcagni ML, et al. The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study. Eur J Nucl Med Mol Imaging. 2019. PMID: 31414206. doi:10.1007/s00259-019-04436-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。